Completed
Phase Not Applicable
Age: 20Years +
All Genders
ID05562960
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Led by National Taiwan University Hospital · Updated on 2026-07-22
5
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody
CONDITIONS
Brief Title
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Who Can Participate
Age: 20Years +
All Genders
Eligibility Criteria
Inclusion Criteria:
- Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.
- Agree to receive plasmapheresis intervention.
- Agree to participate in the trial and receive serial examinations and follow up.
Exclusion Criteria:
- Patients without plasma anti-NRIP autoantibody.
- Patients requiring permanent ventilator support for ALS progression.
- Not able to receive plasmapheresis or trial-related examinations.
- Under pregnancy.
- Blood fibrinogen level less than 50 mg/dl.
- Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here